You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model
SBC: Cytex Therapeutics, Inc. Topic: NIAMSAbstractThe treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutionsLeft untreatedthese lesions tend to degenerate to chronic pain and osteoarthritisOAultimately requiring a total joint replacementFor patients suffering from knee OAandin particularunicompartmental OAunicondylar knee arthroplastyUKAis an available first line treatment option that p ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets
SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC Topic: 100ABSTRACTTechnology to deliveron demandmolecules that bind targets or catalyze reactions of choice has been a goal of chemistry foryearsEven todaytheory is inadequate to support de novo design of receptors having useful affinity or catalysts having useful turnoverThusmany have sought to create those catalysts on a DNA or RNAcollectivelyxNAusing the Darwinism to these biomolecules to evolveunder lab ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of user-friendly fluorescence based assays for marine toxins
SBC: SEATOX RESEARCH INC Topic: 113ABSTRACTHarmful algal bloomsHABsare becoming frequent occurrences off the coasts of the United Stateswith specific instances in the coastal waters of the west coastthe Gulf of Mexicoand the Pacific OceanHistoricallyHABs have been associated with fish kills and marine mammal mortalitieshowevertheir effects on human health and economic loss due to HAB contamination of seafood are becoming more preva ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Microfluidic Nitric Oxide Sensor
SBC: CLINICAL SENSORS, INC. Topic: NIAIDPROJECT SUMMARY Clinical Sensors has developed a manufacturable prototype microfluidic sensor for measuring nitric oxide in whole bloodThis STTR Phase II project aims to complete several key aims necessary to commercialize this deviceincluding a clinical study where NO levels will be evaluated clinically in sepsisSepsis is the leading cause of death in non cardiac intensive care unitsICUsEach year ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Bioimpedance based Intracranial Mapping for Monitoring Evolving TBI
SBC: RYTEK MEDICAL INC Topic: 105ABSTRACT Approximately million individuals suffer from traumatic brain injury TBI annually with over expected to die as a result of their injury In these most severe cases patients are typically admitted to the intensive care unit ICU for continuous monitoring and treatment of their injury Standard monitoring includes implantation of an intracranial pressure ICP sensor arterial ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Design and Development of Immunotolerant S. aureus Biotherapies
SBC: Lyticon LLC Topic: RThe increasing incidence of multi drug resistance in Staphylococcus aureus and other bacteria represents a public health crisisTwo thirds of hospital associated Saureus infections andof those acquired in the community are now methicillin resistantMRSAMRSA causes rtinfections in the US each yearand it is responsible for half of all US deaths caused by drug resistant bacteriaThis threat to public he ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases
SBC: Eyedesis Biosciences, LLC Topic: NPROJECT SUMMARY ABSTRACT Persistent disease activity PDA in spite of anti vascular endothelial growth factor VEGF therapy remains a significant clinical unmet need for patients with neovascular age related macular degeneration NVAMD The purpose of this STTR Phase I grant application is to develop novel therapies that will be effective for the treatment of PDA associated with NVAMD The cu ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Lead Compound Discovery from Engineered Analogs of Occidiofungin
SBC: Sano Chemicals, Inc. Topic: NIAIDProject Summary Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have also revealed that occi ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Developing a small peptide to control autoimmune inflammation in type diabetes
SBC: Op-T-Mune, Inc Topic: NIAIDAbstract Type Diabetes T D affects an ever growing population While this disease typically has been associated with juveniles the disease in adult populations is rapidly increasing The defining clinical component is insulin loss which occurs because of sustained inflammation in the islets At present there is no means to prevent or reverse insulin loss A major inflammatory pathway in T D ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of MTX for the Treatment of KRAS Mutant Colorectal Cancer
SBC: Mekanistic Therapeutics, LLC Topic: NCIPROJECT SUMMARY Mekanistic Therapeutics seeks to design discover and develop anti cancer agents that selectively inhibit multiple oncogenic pathways Its lead agent MTX was discovered in collaboration with the Leopold laboratory at University of Michigan MTX is a novel kinase inhibitor showing early promise for its therapeutic potential against solid cancers refractory to current treatm ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health